Genscript Biotech (1548) Stock Statistics & Valuation Metrics

Genscript Biotech has a market cap or net worth of HK$28.30B. The enterprise value is HK$3.85B.

Genscript Biotech has 2,186,378,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Genscript Biotech’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 0.18%.

The current PE Ratio of Genscript Biotech is ―. Genscript Biotech’s PEG ratio is -0.03.

In the last 12 months, Genscript Biotech had revenue of 594.49M and earned 2.96B in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was 232.62M and capital expenditures -32.13M, giving a free cash flow of 200.49M billion.

Genscript Biotech pays an annual dividend of HK$0.012, resulting in a dividend yield of ―

Genscript Biotech upcoming earnings date is Mar 27, 2026, TBA (Confirmed).

Genscript Biotech as a current ratio of 2.72, with Debt / Equity ratio of 12.42%

In the past 12 months, Genscript Biotech has paid 2.98M in taxes.

Genscript Biotech EV to EBITDA ratio is 47.57, with an EV/FCF ratio of -46.35.

Genscript Biotech has HK$938.36M in cash and marketable securities with HK$548.52M in debt, giving a net cash position of HK$389.84M billion.

Gross margin is 51.78%, with operating margin of 1.56%, and net profit margin of 498.22%.

The average price target for Genscript Biotech is HK$23.88, which is 11.43% higher than the current price. The consensus rating is Moderate Buy